# Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

> **NCT01332188** · PHASE2,PHASE3 · COMPLETED · sponsor: **Aciex Therapeutics, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** AC-170 0.05%
- **DRUG:** AC-170 0.1%
- **DRUG:** AC-170 0.24%
- **DRUG:** AC-170 0%

## Key facts

- **NCT ID:** NCT01332188
- **Lead sponsor:** Aciex Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-06
- **Final completion:** 2011-10
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2017-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332188, "Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01332188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*